Talk:Cabergoline: Difference between revisions
>Dextromethorphan created cabergoline |
>Blackhole added summary sheet and substance box, removed picture |
||
| (6 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
{{headerpanel|{{Stub}}}} | {{headerpanel|{{Stub}}}} | ||
{{SummarySheet}} | |||
'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes | {{SubstanceBox/Cabergoline}} | ||
'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], more specifically, [[AL-LAD]], but instead shares many effects with related, non-psychedelic medicinal compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease. | |||
Cabergoline is not predominantly psychedelic | Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist. | ||
Cabergoline has little recreational value | Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>{{cite journal | vauthors=((Krüger, T. H. C.)), ((Haake, P.)), ((Haverkamp, J.)), ((Krämer, M.)), ((Exton, M. S.)), ((Saller, B.)), ((Leygraf, N.)), ((Hartmann, U.)), ((Schedlowski, M.)) | journal=The Journal of Endocrinology | title=Effects of acute prolactin manipulation on sexual drive and function in males | volume=179 | issue=3 | pages=357–365 | date= December 2003 | issn=0022-0795 | doi=10.1677/joe.0.1790357}}</ref><ref>{{cite journal | vauthors=((Hollander, A. B.)), ((Pastuszak, A. W.)), ((Hsieh, T.-C.)), ((Johnson, W. G.)), ((Scovell, J. M.)), ((Mai, C. K.)), ((Lipshultz, L. I.)) | journal=Sexual Medicine | title=Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis | volume=4 | issue=1 | pages=e28-33 | date= March 2016 | issn=2050-1161 | doi=10.1016/j.esxm.2015.09.001}}</ref> | ||
==See also== | |||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Lysergamide]] | *[[Lysergamide]] | ||
| Line 15: | Line 16: | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/Cabergoline Cabergoline (Wikipedia)] | *[https://en.wikipedia.org/wiki/Cabergoline Cabergoline (Wikipedia)] | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=9594&name=Cabergoline Cabergoline (Isomer Design)] | *[https://isomerdesign.com/PiHKAL/explore.php?id=9594&name=Cabergoline Cabergoline (Isomer Design)] | ||
==References== | ==References== | ||
[[Category:Alkaloid]] | [[Category:Alkaloid]] | ||
[[Category:Lysergamide]] | [[Category:Lysergamide]] | ||
<references /> | |||
Latest revision as of 15:36, 10 October 2023
 |
This article is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
| Summary sheet: Cabergoline |
| Cabergoline | |||||
|---|---|---|---|---|---|
 |
|||||
| Chemical Nomenclature | |||||
| Common names | Cabergoline, Dostinex | ||||
| Systematic name | (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide | ||||
| Class Membership | |||||
| Psychoactive class | Psychedelic | ||||
| Chemical class | Lysergamide | ||||
| Routes of Administration | |||||
|
|||||
Cabergoline is a chemical of the lysergamide and ergopeptine classes. It is a close derivative of LSD, more specifically, AL-LAD, but instead shares many effects with related, non-psychedelic medicinal compounds such as ergotamine, ergonovine or lisuride. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.
Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the dopamine D2 receptor as an agonist but has comparatively little effect on the serotonin 5-HT2A receptor where it acts as a partial agonist.
Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, allowing men to experience multiple ejaculatory orgasms in rapid succession.[1][2]
See also
External links
References
- ↑ Krüger, T. H. C., Haake, P., Haverkamp, J., Krämer, M., Exton, M. S., Saller, B., Leygraf, N., Hartmann, U., Schedlowski, M. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". The Journal of Endocrinology. 179 (3): 357–365. doi:10.1677/joe.0.1790357. ISSN 0022-0795.
- ↑ Hollander, A. B., Pastuszak, A. W., Hsieh, T.-C., Johnson, W. G., Scovell, J. M., Mai, C. K., Lipshultz, L. I. (March 2016). "Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis". Sexual Medicine. 4 (1): e28–33. doi:10.1016/j.esxm.2015.09.001. ISSN 2050-1161.